Finch Therapeutics Group, Inc. logo

Finch Therapeutics Group, Inc.

0001733257

Finch Therapeutics is a biotechnology company focused on developing innovative microbiome assets. The company has a portfolio with potential applicability across a wide range of product strategies and therapeutic areas. They were previously involved in clinical trials for recurrent C. difficile, but are now focused on realizing the value of their IP estate and other assets.

81
Altamente Confiable
Puntuación de Confianza

Registro Oficial

Número de IVA
823433558
Dirección
75 STATE STREET, BOSTON, MA 02109
Códigos de Industria
Biological Products, (No Diagnostic Substances), 2836

Análisis de Calidad IA

Industria
Biotechnology
SSL/HTTPS
Seguro
Correo profesional
No

🌟 Empresas similares de confianza

Context Therapeutics Inc.

Context Therapeutics Inc. logo
86/100 · Altamente Confiable

Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.

2001 MARKET STREET, Estados Unidos
Ver perfil

AGENUS INC

AGENUS INC logo
86/100 · Altamente Confiable

Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.

3 FORBES ROAD, Estados Unidos
Ver perfil

Evaxion A/S

Evaxion A/S logo
77/100 · Confiable

Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.

DR NEERGAARDS VEJ 5F, Estados Unidos
Ver perfil